Regarding molecular-targeted agents for KRAS G12C mutations, sotorasib and adagrasib are now indicated as a second-line treatment following ICI regimens and has expanded the therapeutic options for KRAS-mutant NSCLC patients (54). Here, KRAS is linked to non-small cell lung carcinoma.